Literature DB >> 25097177

miRNA-mRNA integrative analysis in primary myelofibrosis CD34+ cells: role of miR-155/JARID2 axis in abnormal megakaryopoiesis.

Ruggiero Norfo1, Roberta Zini1, Valentina Pennucci1, Elisa Bianchi1, Simona Salati1, Paola Guglielmelli2, Costanza Bogani2, Tiziana Fanelli2, Carmela Mannarelli2, Vittorio Rosti3, Daniela Pietra4, Silvia Salmoiraghi5, Andrea Bisognin6, Samantha Ruberti1, Sebastiano Rontauroli1, Giorgia Sacchi1, Zelia Prudente1, Giovanni Barosi3, Mario Cazzola4, Alessandro Rambaldi5, Stefania Bortoluzzi6, Sergio Ferrari7, Enrico Tagliafico7, Alessandro M Vannucchi2, Rossella Manfredini1.   

Abstract

Primary myelofibrosis (PMF) is a myeloproliferative neoplasm characterized by megakaryocyte (MK) hyperplasia, bone marrow fibrosis, and abnormal stem cell trafficking. PMF may be associated with somatic mutations in JAK2, MPL, or CALR. Previous studies have shown that abnormal MKs play a central role in the pathophysiology of PMF. In this work, we studied both gene and microRNA (miRNA) expression profiles in CD34(+) cells from PMF patients. We identified several biomarkers and putative molecular targets such as FGR, LCN2, and OLFM4. By means of miRNA-gene expression integrative analysis, we found different regulatory networks involved in the dysregulation of transcriptional control and chromatin remodeling. In particular, we identified a network gathering several miRNAs with oncogenic potential (eg, miR-155-5p) and targeted genes whose abnormal function has been previously associated with myeloid neoplasms, including JARID2, NR4A3, CDC42, and HMGB3. Because the validation of miRNA-target interactions unveiled JARID2/miR-155-5p as the strongest relationship in the network, we studied the function of this axis in normal and PMF CD34(+) cells. We showed that JARID2 downregulation mediated by miR-155-5p overexpression leads to increased in vitro formation of CD41(+) MK precursors. These findings suggest that overexpression of miR-155-5p and the resulting downregulation of JARID2 may contribute to MK hyperplasia in PMF.
© 2014 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25097177      PMCID: PMC4186546          DOI: 10.1182/blood-2013-12-544197

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  46 in total

Review 1.  MicroRNAs in acute leukemia: from biological players to clinical contributors.

Authors:  D Schotte; R Pieters; M L Den Boer
Journal:  Leukemia       Date:  2011-06-24       Impact factor: 11.528

Review 2.  MicroRNA function in myeloid biology.

Authors:  Ryan M O'Connell; Jimmy L Zhao; Dinesh S Rao
Journal:  Blood       Date:  2011-07-01       Impact factor: 22.113

Review 3.  microRNA regulation in megakaryocytopoiesis.

Authors:  Huiyuan Li; Haifeng Zhao; Donghai Wang; Renchi Yang
Journal:  Br J Haematol       Date:  2011-09-13       Impact factor: 6.998

4.  Reduced NR4A gene dosage leads to mixed myelodysplastic/myeloproliferative neoplasms in mice.

Authors:  Ashley M Ramirez-Herrick; Shannon E Mullican; Andrea M Sheehan; Orla M Conneely
Journal:  Blood       Date:  2011-01-04       Impact factor: 22.113

Review 5.  New mutations and pathogenesis of myeloproliferative neoplasms.

Authors:  William Vainchenker; François Delhommeau; Stefan N Constantinescu; Olivier A Bernard
Journal:  Blood       Date:  2011-06-07       Impact factor: 22.113

6.  Valproic acid triggers erythro/megakaryocyte lineage decision through induction of GFI1B and MLLT3 expression.

Authors:  Roberta Zini; Ruggiero Norfo; Francesco Ferrari; Elisa Bianchi; Simona Salati; Valentina Pennucci; Giorgia Sacchi; Chiara Carboni; Giovanni Battista Ceccherelli; Enrico Tagliafico; Sergio Ferrari; Rossella Manfredini
Journal:  Exp Hematol       Date:  2012-08-10       Impact factor: 3.084

7.  MicroRNA deregulation in polycythemia vera and essential thrombocythemia patients.

Authors:  Huichun Zhan; Christopher Cardozo; Wayne Yu; Antai Wang; Alison R Moliterno; Chi V Dang; Jerry L Spivak
Journal:  Blood Cells Mol Dis       Date:  2012-12-21       Impact factor: 3.039

8.  Frequent deletions of JARID2 in leukemic transformation of chronic myeloid malignancies.

Authors:  Ana Puda; Jelena D Milosevic; Tiina Berg; Thorsten Klampfl; Ashot S Harutyunyan; Bettina Gisslinger; Elisa Rumi; Daniela Pietra; Luca Malcovati; Chiara Elena; Michael Doubek; Michael Steurer; Natasa Tosic; Sonja Pavlovic; Paola Guglielmelli; Lisa Pieri; Alessandro M Vannucchi; Heinz Gisslinger; Mario Cazzola; Robert Kralovics
Journal:  Am J Hematol       Date:  2011-12-21       Impact factor: 10.047

9.  Integrated analysis of microRNA and mRNA expression profiles in physiological myelopoiesis: role of hsa-mir-299-5p in CD34+ progenitor cells commitment.

Authors:  E Tenedini; E Roncaglia; F Ferrari; C Orlandi; E Bianchi; S Bicciato; E Tagliafico; S Ferrari
Journal:  Cell Death Dis       Date:  2010       Impact factor: 8.469

Review 10.  MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review.

Authors:  Marilena V Iorio; Carlo M Croce
Journal:  EMBO Mol Med       Date:  2012-02-20       Impact factor: 12.137

View more
  46 in total

Review 1.  Setting Appropriate Goals for the Next Generation of Clinical Trials in Myelofibrosis.

Authors:  Giovanni Barosi
Journal:  Curr Hematol Malig Rep       Date:  2015-12       Impact factor: 3.952

2.  Bone marrow-specific loss of ABI1 induces myeloproliferative neoplasm with features resembling human myelofibrosis.

Authors:  Anna Chorzalska; John Morgan; Nagib Ahsan; Diana O Treaba; Adam J Olszewski; Max Petersen; Nathan Kingston; Yan Cheng; Kara Lombardo; Christoph Schorl; Xiaoqing Yu; Roberta Zini; Annalisa Pacilli; Alexander Tepper; Jillian Coburn; Anita Hryniewicz-Jankowska; Ting C Zhao; Elena Oancea; John L Reagan; Olin Liang; Leszek Kotula; Peter J Quesenberry; Philip A Gruppuso; Rossella Manfredini; Alessandro Maria Vannucchi; Patrycja M Dubielecka
Journal:  Blood       Date:  2018-09-13       Impact factor: 22.113

3.  Identification of the Regulatory Elements and Target Genes of Megakaryopoietic Transcription Factor MEF2C.

Authors:  Xianguo Kong; Lin Ma; Edward Chen; Chad A Shaw; Leonard C Edelstein
Journal:  Thromb Haemost       Date:  2019-02-07       Impact factor: 5.249

4.  JARID2 Functions as a Tumor Suppressor in Myeloid Neoplasms by Repressing Self-Renewal in Hematopoietic Progenitor Cells.

Authors:  Hamza Celik; Won Kyun Koh; Ashley C Kramer; Elizabeth L Ostrander; Cates Mallaney; Daniel A C Fisher; Jingyu Xiang; William C Wilson; Andrew Martens; Alok Kothari; Gregory Fishberger; Eric Tycksen; Darja Karpova; Eric J Duncavage; Youngsook Lee; Stephen T Oh; Grant A Challen
Journal:  Cancer Cell       Date:  2018-11-12       Impact factor: 31.743

Review 5.  Genomic landscape of megakaryopoiesis and platelet function defects.

Authors:  Elisa Bianchi; Ruggiero Norfo; Valentina Pennucci; Roberta Zini; Rossella Manfredini
Journal:  Blood       Date:  2016-01-19       Impact factor: 22.113

6.  Loss of the proteostasis factor AIRAPL causes myeloid transformation by deregulating IGF-1 signaling.

Authors:  Fernando G Osorio; Clara Soria-Valles; Olaya Santiago-Fernández; Teresa Bernal; María Mittelbrunn; Enrique Colado; Francisco Rodríguez; Elena Bonzon-Kulichenko; Jesús Vázquez; Montserrat Porta-de-la-Riva; Julián Cerón; Antonio Fueyo; Juan Li; Anthony R Green; José M P Freije; Carlos López-Otín
Journal:  Nat Med       Date:  2015-12-21       Impact factor: 53.440

7.  Normal hematopoiesis and lack of β-catenin activation in osteoblasts of patients and mice harboring Lrp5 gain-of-function mutations.

Authors:  Marta Galán-Díez; Adiba Isa; Marco Ponzetti; Morten Frost Nielsen; Moustapha Kassem; Stavroula Kousteni
Journal:  Biochim Biophys Acta       Date:  2015-12-08

8.  Lipocalin produced by myelofibrosis cells affects the fate of both hematopoietic and marrow microenvironmental cells.

Authors:  Min Lu; Lijuan Xia; Yen-Chun Liu; Tsivia Hochman; Laetizia Bizzari; Daniel Aruch; Jane Lew; Rona Weinberg; Judith D Goldberg; Ronald Hoffman
Journal:  Blood       Date:  2015-05-28       Impact factor: 22.113

9.  MiR-155 enhances phagocytic activity of β-thalassemia/HbE monocytes via targeting of BACH1.

Authors:  Kanitta Srinoun; Chamnong Nopparatana; Malai Wongchanchailert; Suthat Fucharoen
Journal:  Int J Hematol       Date:  2017-07-06       Impact factor: 2.490

10.  Possible role of intragenic DNA hypermethylation in gene silencing of the tumor suppressor gene NR4A3 in acute myeloid leukemia.

Authors:  Ryo Shimizu; Tomoya Muto; Kazumasa Aoyama; Kwangmin Choi; Masahiro Takeuchi; Shuhei Koide; Nagisa Hasegawa; Yusuke Isshiki; Emi Togasaki; Chika Kawajiri-Manako; Yuhei Nagao; Shokichi Tsukamoto; Shio Sakai; Yusuke Takeda; Naoya Mimura; Chikako Ohwada; Emiko Sakaida; Tohru Iseki; Daniel T Starczynowski; Atsushi Iwama; Koutaro Yokote; Chiaki Nakaseko
Journal:  Leuk Res       Date:  2016-09-26       Impact factor: 3.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.